GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Abstract Background The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). Met...

Full description

Bibliographic Details
Main Authors: Jeong A. Park, Nai-Kong V. Cheung
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Journal of Hematology & Oncology
Subjects:
Osteosarcoma
Immunotherapy
Bispecific antibody
Disialogangliosides
Human epidermal growth factor receptor-2
T cell arming
Online Access:https://doi.org/10.1186/s13045-020-01012-y

Internet

https://doi.org/10.1186/s13045-020-01012-y

Similar Items